Dong Xin, Gao Li, Liu Kai, Bai Jiawei, Dong Jiaqiang, Fang Nian, Han Ying, Liu Zhiguo
Xijing Hospital of Digestive Diseases, Air Force Medical University (Fourth Military Medical University), 127 Changle West Road, Xi'an, 710032, Shaanxi, China.
Department of Gastroenterology, The First Hospital of Nanchang (The Third Affiliated Hospital of Nanchang University), Nanchang, China.
Surg Endosc. 2025 Feb;39(2):730-740. doi: 10.1007/s00464-024-11496-1. Epub 2025 Jan 3.
Small gastric subepithelial tumors (SETs) in the stomach can be managed through surveillance or resection. However, it is still controversial how often the lesion would progress if left untreated. This study aimed to evaluate the progression rate of small SETs and identify risk factors influencing tumor growth.
PubMed, Cochrane Library, Web of Science, and Scopus were searched for relevant studies until March 2023. Patient information, endoscopic features of SETs, and surveillance information were extracted from each included study. A random-effects model was applied along with subgroup and sensitivity analyses.
Based on 14 studies with 5405 SETs smaller than 3.5 cm, the annual incidence of size increase was 4.0 (95%CI 2.2-5.8) per 100 person-years, and the overall incidence was 12.8% (95%CI 8.3%-17.3%) across a surveillance duration of 51.3 ± 16.9 months. The predicted risk factors for tumor growth included ≥ 1 cm lesion size (1-2 cm vs. < 1 cm, OR 2.61, 95%CI 1.80-3.79; and > 2 cm vs. 1-2 cm, OR 1.25, 95%CI 0.87-1.81), origin in the muscularis propria (OR 2.09, 95%CI 1.41-3.10), mucosal change (OR 3.27, 95%CI 1.95-5.50), irregular margin (OR 3.16, 95%CI 1.15-8.69), and hypoechoic pattern (OR 3.06, 95%CI 1.34-7.00).
Most small gastric SETs, particularly those smaller than 1 cm, did not increase in size during surveillance. Special attention should be given to lesions larger than 1 cm, originating from the muscularis propria, or exhibiting mucosal change, irregular margin, and hypoechoic pattern.
胃内的小胃黏膜下肿瘤(SETs)可通过监测或切除来处理。然而,如果不进行治疗,病变进展的频率仍存在争议。本研究旨在评估小SETs的进展率,并确定影响肿瘤生长的危险因素。
检索了PubMed、Cochrane图书馆、科学网和Scopus数据库,查找截至2023年3月的相关研究。从每项纳入研究中提取患者信息、SETs的内镜特征和监测信息。应用随机效应模型以及亚组分析和敏感性分析。
基于14项包含5405个直径小于3.5 cm的SETs的研究,每100人年大小增加的年发生率为4.0(95%CI 2.2 - 5.8),在51.3±16.9个月的监测期内总体发生率为12.8%(95%CI 8.3% - 17.3%)。肿瘤生长的预测危险因素包括病变大小≥1 cm(1 - 2 cm对比<1 cm,OR 2.61,95%CI 1.80 - 3.79;>2 cm对比1 - 2 cm,OR 1.25,95%CI 0.87 - 1.81)、起源于固有肌层(OR 2.09,95%CI 1.41 - 3.10)、黏膜改变(OR 3.27,95%CI 1.95 - 5.50)、边缘不规则(OR 3.16,95%CI 1.15 - 8.69)和低回声模式(OR 3.06,95%CI 1.34 - 7.00)。
大多数小胃SETs,尤其是那些小于1 cm的,在监测期间大小没有增加。应特别关注大于1 cm、起源于固有肌层或表现出黏膜改变、边缘不规则和低回声模式的病变。